Baidu
map

J Clin Oncol:高风险和极高风险前列腺癌中仅前列腺与全盆腔放射治疗的比较

2021-02-06 AlexYang MedSci原创

最近,有研究人员报告了一项比较高风险前列腺癌中预防性全盆腔结节放疗与单纯前列腺放疗(PORT)的随机试验临床结果。

最近,有研究人员报告了一项比较高风险前列腺癌中预防性全盆腔结节放疗与单纯前列腺放疗(PORT)的随机试验临床结果

研究为III期、单中心和随机对照试验,共包括了符合条件的患者,这些患者因结节阴性前列腺癌进行了根治性放疗,预估的结节风险≥20%。从2011年11月到2017年8月,共有224名患者随机分配(PORT=114,WPRT=110)。在随访中位数为68个月中,记录了36例生化失败(PORT=25例,WPRT=7例)和24例死亡(PORT=13例,WPRT=11例)。WPRT的5年BFFS为95.0%(95%CI,88.4-97.9),而PORT为81.2%(95%CI,71.6-87.8),未经调整的风险比(HR)为0.23(95%CI,0.10-0.52;P<0.0001)。WPRT同时也显示出更高的5年DFS(89.5% v 77.2%;HR,0.40;95%CI,0.22至0.73;P=0.002),但5年OS没有差异(92.5% v 90.8%;HR,0.92;95%CI,0.41至2.05;P=0.83)。另外,WPRT的远处无转移生存期也较高(95.9% v 89.2%;HR,0.35;95%CI,0.15至0.82;P=0.01)。在不同预后亚组中,BFFS和DFS的获益得以维持。

最后,研究人员指出,与PORT相比,高风险和局部晚期前列腺癌的预防性盆腔照射可改善BFFS和DFS,但OS没有差异

原始出处:

Vedang Murthy , Priyamvada Maitre , Sadhana Kannan et al. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol. Jan 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866006, encodeId=fa7e186600650, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 05 04:14:09 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862150, encodeId=f3e91862150bf, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Oct 17 20:14:09 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038208, encodeId=7169103820898, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040950, encodeId=7547104095000, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-09-05 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866006, encodeId=fa7e186600650, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 05 04:14:09 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862150, encodeId=f3e91862150bf, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Oct 17 20:14:09 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038208, encodeId=7169103820898, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040950, encodeId=7547104095000, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866006, encodeId=fa7e186600650, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 05 04:14:09 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862150, encodeId=f3e91862150bf, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Oct 17 20:14:09 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038208, encodeId=7169103820898, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040950, encodeId=7547104095000, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-06 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1866006, encodeId=fa7e186600650, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 05 04:14:09 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862150, encodeId=f3e91862150bf, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Oct 17 20:14:09 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038208, encodeId=7169103820898, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040950, encodeId=7547104095000, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 06 19:14:09 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-06 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

ACS Nano :“撒泡尿照照”!AI诊断前列腺癌全新突破,只需20分钟,准确性近100%

前列腺癌是男性癌症死亡的主要原因之一。然而,由于现阶段的检测水平有限,前列腺癌的诊断率一直处于较低的水平。这也给治疗前列腺癌带来了很大的难度,因为发现时可能癌细胞已经转移或扩散。

J Clin Oncol:全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后

体外放射治疗联合雄激素剥夺治疗(ADT)是非转移性的局部晚期前列腺癌的推荐的根治性治疗。本文报道了一项随机试验,比较了预防性全盆腔淋巴结放疗(WPPT)和单纯前列腺放疗(PORT)治疗高危型前列腺癌的

Int J Nanomedicine:外泌体通过上调血红素加氧酶-1促进雄激素依赖性前列腺癌细胞向不依赖雄激素转变

去势抵抗性前列腺癌(CRPC)仍不能治愈,尽管CRPC的机制已有广泛研究。研究表明,肿瘤微环境中的外泌体有利于前列腺癌的发展和进展。然而,外泌体在CRPC进展过程中的作用尚未确定。

Prostate Cancer P D:非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较:倾向性评分匹配研究

局部治疗(FT)切除的是前列腺癌的部分区域,而不是整个腺体。最近,有研究人员比较了FT与根治性前列腺切除术(RP)的肿瘤学结果。

Eur Radiol:对于低风险局灶性前列腺癌,MRI上哪些征象提示肿瘤进展呢?

有些前列腺癌病灶处在进展低风险时,直接做手术有点不值当的,不做手术吧又有点不放心!那对于这样的前列腺癌,我们该拿它如何是好呢?

Clin Cancer Res:PSMA靶向AMG160疗法在转移去势抵抗性前列腺癌临床前模型中具有强效的抗肿瘤活性

转移去势抵抗性前列腺癌(mCRPC)仍然是一种远未满足医疗需求的疾病,因为大多数患者在现有的治疗方法中不能获得持续的响应。前列腺特异性膜抗原(PSMA)是mCRPC的一个引人注目的靶标,其在原发性和转

Baidu
map
Baidu
map
Baidu
map